1
|
Wickersham KE, Crothers M, Puth D, Weiss MN, Powell K, Resnick B. Targeted therapy use in adults with cancer ≥85 years of age. Geriatr Nurs 2018; 40:63-66. [PMID: 30327159 DOI: 10.1016/j.gerinurse.2018.06.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2018] [Revised: 06/11/2018] [Accepted: 06/15/2018] [Indexed: 12/20/2022]
Abstract
PURPOSE Assess patient- and clinical-related variables associated with targeted cancer treatments (TTs) for adults ≥85 years of age. RATIONALE TTs have pathway-specific side effects that negatively affect QoL and medication adherence, which may reduce TT efficacy. Research has not focused on patients aged ≥85 years; therefore, the scope of TT use in this age group is not understood. METHODS We conducted an electronic medical record review to identify individuals ≥85 years treated with TT. RESULTS The sample (N = 295) was 53.5% male, 41% married/partnered, and 73.7% Caucasian. Common cancer types included breast (26.3%), prostate (31.3%), and leukemia (14.1%). Only one-third (n = 98) of the sample had TT side effects noted in their patient chart. CONCLUSIONS Patients aged ≥85 years took similar TTs and experienced similar side effects as reported by research of younger patients; however, symptom experience was not well-reported.
Collapse
Affiliation(s)
- Karen E Wickersham
- School of Nursing, University of Maryland, Baltimore, Baltimore, Maryland, USA.
| | - Molly Crothers
- School of Nursing, University of Maryland, Baltimore, Baltimore, Maryland, USA
| | - Danielle Puth
- School of Nursing, University of Maryland, Baltimore, Baltimore, Maryland, USA
| | - Miriam N Weiss
- School of Nursing, University of Maryland, Baltimore, Baltimore, Maryland, USA
| | - Kendall Powell
- School of Nursing, University of Maryland, Baltimore, Baltimore, Maryland, USA
| | - Barbara Resnick
- School of Nursing, University of Maryland, Baltimore, Baltimore, Maryland, USA
| |
Collapse
|
2
|
Korkmaz S, Dal MS, Berber I, Sahin DG, Dogu MH, Ayyildiz O, Nizam I, Albayrak M, Esen R, Namdaroglu S, Sencan M, Akay OM, Hacioglu S, Yildirim R, Eser A, Tombak A, Pala C, Ilhan O. Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study. Geriatr Gerontol Int 2014; 15:729-35. [PMID: 25257190 DOI: 10.1111/ggi.12341] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 05/20/2014] [Indexed: 11/28/2022]
Abstract
AIMS We aimed to investigate whether older age leads to limitations in the starting dose of imatinib in daily treatment of chronic myeloid leukemia, and to determine the compliance of elderly patients with tyrosine kinase inhibitors (TKI) therapy. METHODS Data including the clinical characteristics, therapeutic outcomes and compliance with TKI therapy of elderly patients with chronic myeloid leukemia aged >65 years were collected from 13 institutions in Turkey, retrospectively. RESULTS A total of 69 patients (27 [39%] men, 42 [61%] women) were evaluated retrospectively. The median age of the patients was 71 years (range 66-85 years). Of the patients, 66 (96%) were in the chronic phase and three (4.3%) were in the accelerated phase when diagnosed. A total of 63 (91.3%) patients were receiving imatinib as the first-line therapy. The initial dose of imatinib was 400 mg/day in 59 patients (93.6%). Imatinib treatment induced 57 (90.5%) complete hematological responses at 3 months, 29 (46%) complete cytogenetic responses at 6 months and 49 (77.7%) major molecular responses at 12 months. As a result, nilotinib and dasatinib were used in 14 patients as second-line therapy. Second-line TKI induced nine complete hematological responses (64.3%) at 3 months, four complete cytogenetic responses (28.6%) at 12 months and seven major molecular responses (50%) at 18 months. A total of 56 of the patients (81.2%) are still alive. The median overall survival and progression-free survival rates were 35 months (range 1-95 months) and 17 months (range 0.8-95 months), respectively. CONCLUSION Elderly patients should receive TKI according to the same guidelines that apply to younger patients.
Collapse
Affiliation(s)
- Serdal Korkmaz
- Division of Hematology, Kayseri Education and Research Hospital, Kayseri, Turkey
| | | | - Ilhami Berber
- Department of Hematology, Inonu University, Malatya, Turkey
| | | | | | - Orhan Ayyildiz
- Department of Hematology, Dicle University, Diyarbakir, Turkey
| | - Ilknur Nizam
- Department of Hematology, Inonu University, Malatya, Turkey
| | - Murat Albayrak
- Department of Hematology, Diskapi Yildirim Beyazit Education and Research Hospital, Ankara, Turkey
| | - Ramazan Esen
- Department of Hematology, Yuzuncu Yil University, Van, Turkey
| | - Sinem Namdaroglu
- Department of Hematology, Ankara Oncology Education and Research Hospital, Ankara, Turkey
| | - Mehmet Sencan
- Department of Hematology, Cumhuriyet University, Sivas, Turkey
| | - Olga Meltem Akay
- Department of Hematology, Osmangazi University, Eskisehir, Turkey
| | - Sibel Hacioglu
- Department of Hematology, Pamukkale University, Denizli, Turkey
| | - Rahsan Yildirim
- Department of Hematology, Ataturk University, Erzurum, Turkey
| | - Ali Eser
- Department of Hematology, Marmara University, Istanbul, Turkey
| | - Anil Tombak
- Department of Hematology, Mersin University, Mersin, Turkey
| | - Cigdem Pala
- Department of Hematology, Erciyes University, Kayseri, Turkey
| | - Osman Ilhan
- Department of Hematology, Ibni Sina Hospital, Ankara University, Ankara, Turkey
| |
Collapse
|